Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Salvatore Provenzano, Roberta Sanfilippo, Carlo Morosi, Vittoria Colia, Rossella Bertulli, Paola Collini, Paolo G. Casali, Alessandro Gronchi, Silvia Stacchiotti, Elena Fumagalli
Publikováno v:
Sarcoma, Vol 2017 (2017)
Sarcoma
Sarcoma
Background. To report on the activity of high-dose prolonged-infusion ifosfamide (HDIFX) chemotherapy in a retrospective series of patients affected by myxoid liposarcoma treated at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. Pati
Publikováno v:
Sarcoma, Vol 2016 (2016)
Sarcoma
Sarcoma
Myxoid liposarcoma is a rare form of soft-tissue sarcoma. Although most patients initially respond well to treatment, approximately 21% relapse, highlighting the need for alternative treatments. To identify novel treatment regimens and gain a better
miR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma
Autor:
Tadashi Kondo, Daisuke Kubota, Yasuhito Arai, Nobuyoshi Kosaka, Takahiro Ochiya, Tomohiro Fujiwara, Akira Kawai, Akihiko Yoshida, Zhiwei Qiao, Fumitaka Takeshita
Publikováno v:
Sarcoma, Vol 2016 (2016)
Sarcoma
Sarcoma
Osteosarcoma is the most common primary malignancy in bone. Patients who respond poorly to induction chemotherapy are at higher risk of adverse prognosis. The molecular basis for such poor prognosis remains unclear. We investigated miRNA expression i
Autor:
Rashmi Chugh, Raphael E. Pollock, Suzanne George, Scott H. Okuno, Edwin Choy, Antje Hoering, Karla V. Ballman, Shreyaskumar Patel, James L. Chen, Rajiv M. Patel, Mark A. Dickson
Publikováno v:
Sarcoma, Vol 2018 (2018)
Sarcoma
Sarcoma
Histone deacetylase inhibitors (HDACi) can reverse chemoresistance, enhance chemotherapy-induced cytotoxicity, and reduce sarcoma proliferation in cell lines and animal models. We sought to determine the safety and toxicity of mocetinostat and its ab
Autor:
Pejman Ghanouni, Everett J. Moding, Raffi S. Avedian, Lynn Million, Christian A. Kunder, Kristen N. Ganjoo
Publikováno v:
Sarcoma, Vol 2017 (2017)
Sarcoma
Sarcoma
Desmoid tumors are locally aggressive fibroproliferative neoplasms that can lead to pain and dysfunction due to compression of nerves and surrounding structures. Desmoid tumors often progress through medical therapy, and there is frequently a delay o
Autor:
Annelies Requilé, Daphne Hompes, Patrick Schöffski, Raf Sciot, Herlinde Dumez, Friedl Sinnaeve, Erik Van Limbergen, Paul Clement, Oliver Bechter, Annelies Verbiest
Publikováno v:
Sarcoma, Vol 2017 (2017)
Sarcoma
Sarcoma
The treatment of Ewing sarcoma (ES) in adult patients requires a multidisciplinary approach. Systemic therapy remains an important component of clinical management of this disease. ES is extremely rare in adult patients. Due to the rarity of the dise
Autor:
Robin L. Jones, Akmal Safwat, Poul Knoblauch, Maja Lind-Hansen, Ian Judson, Anders Krarup-Hansen, Philip Rossen, Joanna Vitfell-Rasmussen
Publikováno v:
Sarcoma, Vol 2016 (2016)
Vitfell-Rasmussen, J, Judson, I, Safwat, A A, Jones, R L, Rossen, P B, Lind-Hansen, M, Knoblauch, P & Krarup-Hansen, A 2016, ' A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas ', Sarcoma, vol. 2016, 2090271 . https://doi.org/10.1155/2016/2090271
Vitfell-Rasmussen, J, Judson, I, Safwat, A, Jones, R L, Rossen, P B, Lind-Hansen, M, Knoblauch, P & Krarup-Hansen, A 2016, ' A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas ', Sarcoma, vol. 2016, 2090271 . https://doi.org/10.1155/2016/2090271
Sarcoma
Vitfell-Rasmussen, J, Judson, I, Safwat, A A, Jones, R L, Rossen, P B, Lind-Hansen, M, Knoblauch, P & Krarup-Hansen, A 2016, ' A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas ', Sarcoma, vol. 2016, 2090271 . https://doi.org/10.1155/2016/2090271
Vitfell-Rasmussen, J, Judson, I, Safwat, A, Jones, R L, Rossen, P B, Lind-Hansen, M, Knoblauch, P & Krarup-Hansen, A 2016, ' A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas ', Sarcoma, vol. 2016, 2090271 . https://doi.org/10.1155/2016/2090271
Sarcoma
Background. Belinostat is a novel histone deacetylase inhibitor.Primary Objectives. Maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of belinostat (Bel) in combination with doxorubicin (Dox) in solid tumours (phase I) and response rat
Autor:
Brittany Lala, Armando Sanchez, Mark A. Dickson, William D. Tap, Mary Louise Keohan, C. Okoli, Sandra P. D'Angelo, Aimee M. Crago, Ping Chi, N. Schmidt, Alexander N. Shoushtari, Jonathan Landa, Deborah Kuk, Mrinal M. Gounder
Publikováno v:
Sarcoma, Vol 2016 (2016)
Sarcoma
Sarcoma
Background. Leiomyosarcomas (LMS) represent a heterogeneous subset of soft tissue sarcomas. Factors influencing prognosis for patients with metastatic extrauterine LMS (euLMS) are not well described. Limited data are available regarding responses to